Roseway labs plans EU launch

Roseway Labs, specialist in providing personalised medication, has announced plans to bring its services to the European Union (EU) prescribers.

Founded in 2018 by chief executive Elizabeth Philp and superintendent pharmacist Miriam Martinez Callejas, Roseway’s driving passion was to provide solutions for patients with special medical needs, and give prescribers access to hard-to-find medication.

Branching out to the EU is the next phase of growth for the company. Once all the regulatory work has been completed, Roseway plans to open its new base in the Netherlands in Spring 2024.

“We know people who live in the EU and come to the UK for medicine, so we're just bringing that to them”, Philp says. “We'll also be taking some of our UK clients with us and enabling them to access the EU market, whether it's giving people access to Bioidentical Hormone Replacement Therapy (BHRT), skin creams or solutions for hair loss to pain management, allergies and intolerances or nutrition. There are a few market dynamics that will be different. While being part of the EU in the same framework, each country has different rules, so we will need to navigate those.”

Once the base opens, prescribers will be able to set up an account and, after a verification and due-diligence process, will have access to eRoseway, Roseway Labs’ state-of-the-art electronic prescribing system, and submit prescriptions, which will then be dispensed directly to the patient.

“Our market is prescribers with the right attitude who want something that really fits their patients. People who think differently and who want to access something different, to provide a truly personalised service to support their patients’ health and wellness”, furthers Philp. “We are excited at the prospect of bringing our services to prescribers in the EU and look forward to building new relationships.”